June 2026 Research Update

This month added small but concrete real-world examples of what advanced care can look like in primary hyperoxaluria type 1 (PH1) when kidney disease is already severe. Across these reports, transplantation was described as a way to stabilize kidney function and stop dialysis in the short term, and later life goals like dental rehabilitation were also possible in one transplant recipient. Because these are individual cases, they show what can happen for some people rather than what will happen for most. [1] [2]

In one 18-year-old with PH1 and end-stage kidney disease, a simultaneous liver-kidney transplant was followed by stable kidney function and stopping dialysis, with no acute rejection reported during short follow-up. The report connects this to the basic PH1 problem: the liver is where the enzyme defect lives, so replacing the liver aims to stop ongoing oxalate overproduction. This helps illustrate why a combined transplant is sometimes discussed for advanced PH1 rather than a kidney transplant alone. [1]

A separate case focused on life after transplant rather than the transplant itself. A person with PH1 who previously had a combined liver-kidney transplant underwent implant-supported dental rehabilitation, and follow-up to 14 months reported stable implant conditions with no detected complications. The authors framed this as feasible in selected patients when risks are carefully assessed and monitored. [2]

For patients and caregivers, these reports mainly add practical context about later-stage PH1 care rather than changing anything immediately. They show that some people with advanced PH1 can have stable early outcomes after combined liver-kidney transplantation, and that additional procedures (like dental implants) may be possible after transplant in at least one carefully managed case. What remains uncertain is how often these outcomes occur, since case reports cannot estimate typical results or risks across the wider PH1 community. [1] [2]

This month, studies looking at diagnosis and long-term kidney outcomes reinforced a simple picture: primary hyperoxaluria is uncommon but can be a major driver of kidney damage, so confirming the cause matters. A long-term adult cohort found PH stood out as a strong predictor of progression to end-stage kidney disease compared with other inherited stone disorders, while a pediatric survey reported that many genetically confirmed children eventually needed kidney replacement therapy. Case reports added reminders that genetic testing and kidney imaging can be key pieces of putting the diagnosis together. [3] [4] [5] [6]

In a Tunisian adult cohort followed for a long period, people with hereditary stone disorders who had primary hyperoxaluria had faster kidney function decline than those with other causes, and PH was reported as the only independent predictor of end-stage kidney disease in their analysis. The study also described episodes of acute kidney injury in a small number of patients, and in these cases the kidney injury did not reverse. For patients, this supports the idea that PH is not just a stone condition; it can be a condition that threatens kidney function over time. [3]

In an Iranian multicenter survey of children with suspected primary hyperoxaluria, PH was genetically confirmed in 80 children, and AGXT changes (linked to PH1) were the most frequently reported genetic finding. The majority of these patients required kidney replacement therapy, while combined or sequential liver-kidney transplantation was less common. The authors also noted that conservative approaches were used before end-stage kidney disease, reflecting how care often changes as kidney function worsens. [4]

Two case reports highlighted the tools used to reach a specific PH1 diagnosis. One described a family with a newly identified AGXT gene change, presenting with kidney stones and progression to end-stage kidney disease, and emphasized genetic testing as the gold standard for diagnosis. Another described a woman where kidney imaging helped point to PH1 as the underlying cause of nephrocalcinosis and stones, and was used for follow-up. [5] [6]

For patients, this set of studies mainly adds understanding of why getting the right underlying diagnosis matters in stone disease and nephrocalcinosis. The adult cohort and pediatric survey both point in the same direction: once PH is present, the risk of serious kidney decline is not rare in these reported groups. What is still unclear is how these numbers apply to all PH patients, because the studies come from specific centers and populations and do not capture everyone with milder disease. [3] [4] [5] [6]

This month included early treatment research that stays firmly in the laboratory, but it sharpens what may be technically possible in the future. Researchers tested a gene-editing strategy aimed at lowering oxalate production by disrupting HAO1 in the liver. In mice that model PH1, urine oxalate fell by 75% at the highest dose tested, and in rhesus macaques the approach produced dose-dependent liver editing with reported good tolerability. [7]

The study reported that gene editing in PH1-model mice reached over 30% in the liver, and the highest dose led to a 75% drop in urine oxalate along with higher glycolate levels (a related chemical change expected from blocking HAO1). In rhesus macaques, the researchers observed dose-dependent editing in the liver and changes in blood glycolate levels that matched the degree of editing. This connects the proposed mechanism to measurable body changes, which is a key step before human testing can be considered. [7]

For patients, this does not provide evidence about benefits or risks in people yet, because it was done in mice and nonhuman primates. What it adds now is a clearer sense that long-lasting approaches aimed at lowering oxalate production are being explored beyond currently available options, and that researchers can measure both gene editing in the liver and related chemical changes. The biggest uncertainty is how safe and effective this kind of approach would be in humans, since animal results do not reliably predict patient outcomes. [7]